Pfizer will discontinue the global development and commercialization of its FDA-approved hemophilia B gene therapy,
fidanacogene elaparvovec-dzkt (Beqvez), according to recent reports. The company cited "the limited interest patients and their doctors have demonstrated in hemophilia gene therapies" in a statement to
Nikkei Asia.
Pfizer will instead focus on alternative hemophilia treatments, including marstacimab-hncq (Hympavzi), which received
FDA approval in October for routine prophylaxis in hemophilia A and B. Marstacimab is the first anti-tissue factor pathway inhibitor approved in the U.S. and the first hemophilia therapy available in a pre-filled, auto-injector pen.
